CSF2 and schizophrenia: A study by Girgis et al., 2018 [71], on tocilizumab with 36 patients with schizophrenia or schizoaffective disease with a PANSS total of >60 found, before adjusting for multiple testing, that higher GM-CSF at baseline correlated with better treatment efficacy in PANSS total and PANSS positive.